Aligos Therapeutics, Inc. (ALGS) is experiencing a significant drop in its stock price today, despite the recent positive news of its drug ALG-801 receiving FDA orphan drug designation for the treatment of pulmonary arterial hypertension (PAH). The designation highlights the drug's novel therapeutic potential and its promising results in phase 1 trials. However, the market reaction appears to be negative, p
Aligos Therapeutics, Inc. (ALGS) saw its stock price rise by 3.89% to close at $39.84 on December 20, 2024, following a day of heightened trading activity with a volume of 468,705 shares, significantly above its average. The stock opened at $36.76 and reached an intraday high of $41.64, reflecting investor enthusiasm. This uptick is largely attributed to the recent announcement by Ipsen regarding the launch
Aligos Therapeutics, Inc. (ALGS) is seeing an uptick in its stock price today, likely driven by recent developments in treatments for Alagille Syndrome (ALGS). Ipsen has announced the launch of KAYFANDA® (odevixibat), a new treatment for cholestatic pruritus in patients with ALGS aged six months or older. This drug is the first ileal bile acid transporter inhibitor (IBATi) to be tested in a robust Phase III
Aligos Therapeutics, Inc. (ALGS) is experiencing a notable increase in its stock price today, likely influenced by recent developments related to Livmarli®, a treatment for Alagille Syndrome (ALGS). On December 18, 2024, CANbridge Pharmaceuticals announced that the Taiwan Food and Drug Administration has expanded the label for Livmarli to include patients as young as two months old. This expansion could pot
Aligos Therapeutics, Inc. is experiencing a notable uptick in its stock price following the announcement of inducement grants under Nasdaq listing rules. On December 13, 2024, the company disclosed that its Compensation Committee granted a non-qualified stock option to purchase 5,500 shares to a newly hired employee. This grant, part of Aligos' 2024 Inducement Plan, is intended to attract new talent and is